Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

Multiple myeloma has a continued need for more effective and durable therapies. B cell maturation antigen (BCMA), a plasma cell surface antigen and member of the tumor necrosis factor (TNF) receptor superfamily, is an attractive target for immunotherapy of multiple myeloma due to its high prevalence...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Bu, De-Xiu, Singh, Reshma, Choi, Eugene E., Ruella, Marco, Nunez-Cruz, Selene, Mansfield, Keith G., Bennett, Paul, Barton, Nathanial, Wu, Qilong, Zhang, Jiquan, Wang, Yongqiang, Wei, Lai, Cogan, Shawn, Ezell, Tucker, Joshi, Shree, Latimer, Kellie J., Granda, Brian, Tschantz, William R., Young, Regina M., Huet, Heather A., Richardson, Celeste J., Milone, Michael C.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995247/
https://ncbi.nlm.nih.gov/pubmed/29899820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25359
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires